Format

Send to

Choose Destination
Diabetes. 2017 Apr;66(4):806-814. doi: 10.2337/db16-0779. Epub 2016 Dec 2.

Metabolite Profiling of LADA Challenges the View of a Metabolically Distinct Subtype.

Author information

1
Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
2
H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
3
Diabetes and Endocrinology, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
4
Translational Diabetes Research, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
5
Finnish Institute for Molecular Medicine (FIMM), Helsinki University, Helsinki, Finland.
6
Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden peter.spegel@chem.lu.se.
7
Centre for Analysis and Synthesis, Department of Chemistry, Lund University, Lund, Sweden.

Abstract

Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)-positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA from type 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide-driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.

PMID:
27913577
DOI:
10.2337/db16-0779
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center